631911-91-6Relevant articles and documents
Design and synthesis of polyethylene glycol-modified biphenylsulfonyl- thiophene-carboxamidine inhibitors of the complement component C1s
Subasinghe, Nalin L.,Khalil, Ehab,Travins, Jeremy M.,Ali, Farah,Ballentine, Shelley K.,Hufnagel, Heather R.,Pan, Wenxi,Leonard, Kristi,Bone, Roger F.,Soll, Richard M.,Crysler, Carl S.,Ninan, Nisha,Kirkpatrick, Jennifer,Kolpak, Michael X.,Diloreto, Karen A.,Eisennagel, Stephen H.,Huebert, Norman D.,Molloy, Christopher J.,Tomczuk, Bruce E.,Gaul, Michael D.
, p. 5303 - 5307 (2012/09/07)
Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, an
Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
-
, (2008/06/13)
Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.